Human IL6 is a cytokine produced by many cell types that has pleiotropic effects. In
agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and …

The development and effectiveness of novel therapies in multiple myeloma have been
established in large clinical trials. However, multiple myeloma remains an incurable …

Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma
cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of …

We compared the safety and efficacy of siltuximab (S), an anti‐interleukin‐6 chimeric
monoclonal antibody, plus bortezomib (B) with placebo (plc)+ B in patients with …

Acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), and multiple
myeloma (MM) are age-related haematological malignancies with defined precursor states …

The recent understanding of plasma cell (PC) biology has been obtained mainly from
murine models. The current concept is that plasmablasts home to the BM and further …

Purpose: In multiple myeloma, extramedullary progression is associated with treatment
resistance and a high mortality rate. To understand the molecular mechanisms controlling …

CTCF and cohesin play a key role in organizing chromatin into topologically associating
domain (TAD) structures. Disruption of a single CTCF binding site is sufficient to change …

Long-lived plasma cells survive in a protected microenvironment for years or even a lifetime
and provide humoral memory by establishing persistent Ab titers. Long-lived autoreactive …